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Background
HIV rapid diagnostic tests (RDTs) have enabled widespread implementation of HIV programmes and surveillance in resource-limited settings. RDTs can be performed with minimum training, do not require laboratory facilities or expensive equipment and are often supplied as self-contained kits. RDTs improve uptake of test results since testing can be performed at the point of care and the result obtained during a single visit.
The reliability of HIV RDTs has been shown to be equivalent to that of laboratory-based immunoassay methods (apart from during very early seroconversion), and World Health Organization (WHO) guidelines recommend HIV diagnostic algorithms that use only RDTs [1] [2] [3] . A minimum of two positive HIV test results, or three where HIV prevalence is <5%, are needed for a positive diagnosis [1, [4] [5] [6] .
False positive results with HIV RDTs have been widely reported and attributed to a variety of causes [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . They usually lead to discordant test results, which delay diagnosis and, if the frequency of discordant results is high, undermine confidence in testing. However, if the tests used in the diagnostic algorithm are susceptible to the same cause for false positivity this may lead to a false positive HIV diagnosis with potentially devastating consequences for individuals [18] . In resource-limited settings, the current common lack of routine laboratory confirmatory or follow-up testing means that a false diagnosis may not be detected; therefore specificity in these settings is of far greater importance than in resource-rich settings where a false diagnosis will be quickly discovered during the plethora of testing and review following diagnosis [19] .
The WHO/UNAIDS HIV test evaluation programme was developed to provide independent, standardized assessment of HIV tests [2, [20] [21] [22] . Their data, shown in Table 1 , indicate that HIV RDTs do not have 100% specificity. Field trial data (Table 2 ) often demonstrate lower specificity than WHO panel results [23] . Even a minor loss of specificity can significantly reduce the positive predictive value of a test when HIV prevalence is low [1, 24, 25] . This is particularly important if the tests used in a diagnostic algorithm are not independent and/or are susceptible to the same interference.
WHO recommends that HIV RDTs are evaluated at the national level before implementation [1] and there are comprehensive guidelines [6] for development of a diagnostic algorithm for a particular setting. However, implementation of these guidelines is generally beyond the capacity of smaller or less well-resourced programmes or not supported by funding bodies, and in many cases tests are introduced and algorithms formulated without prior local validation [26] . Even if evaluation guidelines can be followed, they assume that the target population remains serologically stable. Médecins Sans Frontières' field experience has been that individual programmes continuing to use the same RDTs can experience significant fluctuations in the frequency and nature of discordant results [27] .
A 'test and treat' strategy for well individuals in settings that are hyperendemic for HIV has been much debated [28, 29] . If it is widely adopted it could exacerbate the consequences of incorrect HIV diagnoses, with possible treatment toxicity and associated costs added to their already huge personal and social implications [18] .
In this article we discuss some of the evidence for commonly cited causes of false positive RDT results for HIV. We hypothesize that, in some settings, false positive results may be more common than the specificities quoted by manufacturers and those determined by the WHO Independent Testing Program suggest [2, [20] [21] [22] , and that they might often be caused by non-specific serological interference. Serological interference may be more common in resource-limited settings, where the testing algorithm is dependent on RDTs alone and where confirmatory testing is usually not available [20] [21] [22] . An understanding of the factors that may influence RDT results is critical to developing reliable HIV diagnostic algorithms in resource-limited settings and to the safety of rolling out wide-scale access to HIV testing and early antiretroviral therapy initiation.
Causes of false positive RDT results
False positive RDT results can be caused by user error such as misinterpretation, clerical mistakes and cross-contamination between blood samples [30] [31] [32] [33] [34] . Accuracy in test performance can also be negatively affected by gaps in quality assurance during the manufacturing process, or by manufacturers introducing changes in the source of the antigen/antibody without changing the name of the product. At the field level, training and supervision in association with quality control procedures are critically important in the roll out of these tests. However false positive results caused by cross-reactivity or non-specific serological reactivity/interference will not be correctable by training in correct test use. 
Issues with test manufacture and interpretation
Limited and overlapping target antigens
HIV RDTs use a restricted number of HIV viral target antigens, often the envelope antigens gp160/gp120/gp41 only or these in combination with p24 (HIV1) and/or gp36 (HIV-2), with a positive result indicating the presence of antibodies to any of the included antigens [34, 35] . This is in contrast to the multiple distinct bands relating to individual antigens that are used to define a positive western blot and LIA test. The limited number of target antigens and common signal increases the susceptibility of HIV RDTs to false positive results.
WHO testing guidelines recommend standardized testing strategies based on a limited number of tests, to 'maximize the accuracy of test results while minimizing cost' [36] . They also specify that HIV assays included in a testing algorithm should have different antigen preparations and test kit components. However, in practice, detailed information about the antigens in a test is often not readily available and there is likely to be significant overlap between the target antigens used in different brands of test. In addition, manufacturers are increasingly providing semi-finalized or finalized products to re-branders/re-labellers, which makes it difficult to determine an assay's provenance. In at least one case, two identical 
Over-interpretation of weak reactivity
Although weak reactivity has been demonstrated to have low specificity in some settings, manufacturers' instructions commonly direct that any reactivity, weak or strong, should be interpreted as a positive result [7] [8] [9] . For example, a study in south-western Uganda [9] reported a false positive rate of 43.9% (129/295 positive results) among 1517 patients using a 'tie-breaker' algorithm (Determine, STAT-PAK, Uni-Gold). Thirty-seven tests were found to have weak bands and exclusion of these results reduced the false positive rate to 2.3% (2/86). 123/129 false positives resulted from Determine HIV-1/2 and Uni-Gold HIV tests. The weak bands were confirmed as false positives on re-assay by an independent laboratory (Centers for Disease Control and Prevention). Similarly a false positive rate of 10.5% in eastern Democratic Republic of Congo (DRC) was shown to be largely attributable to weak false positive RDT bands (Determine HIV-1/2 and UniGold HIV) [7] . The false positive rate fell from 10.5% to 3.3% when only strong positive results were included.
In a cohort study to determine HIV prevalence in over 15,000 people older than 2 years from south-west Tanzania In the large cohort study from Tanzania discussed earlier in the section on weak bands, an association with lower altitude for Determine HIV-1/2 was significant on multivariable analysis, leading the authors to postulate an association with other infections (more common with higher ambient temperature found at lower altitudes) [38] . However they did not find an association with any specific infection for which they tested, including schistosomiasis. A univariable association with P. falciparum infection became nonsignificant on multivariable analysis. It is of note that half the participants with false positive
Determine RDT results were still false positive when re-tested with the Determine RDT one year later. 
Human African trypanosomiasis (HAT)
Malaria
Fonseca et al. [50] reported a strong correlation between malaria and HIV false positive results in one of three immunoassay tests in a sample population of migrant workers in Brazil; however, other studies have found no such association [45, 51, 52] . In addition, for two of the three tests, specificity was within the manufacturers' ranges, suggesting a testspecific problem (discussed later in more detail).
In their study reporting an association between malaria infection and false positive 1 st and 2 nd generation RDT results, Gasasira et al. [16] also found a strong association between younger age and false positive immunoassay and indeterminate western blot reactions, noting that younger persons with a 'less developed immune response to malaria are more likely to exhibit non-specific B-cell stimulation'.
Environmental factors
Populations Meles et al. [54] report a correlation between HIV RDT false positivity and low haemoglobin.
However the authors note that this may also be associated with poverty, in that poverty is likely to be associated with increased exposure to infections and hence an increased level of CD5+ B-cells.
The implication for HIV diagnostics is that patients in resource-limited settings are likely to have an augmented and broader range of cross-reacting antibodies. If this is the case then, while co-infection will likely increase the occurrence of false positive test results, the effect is indirect and not caused by cross-reactivity with a specific antigen present in the infectious agent.
Genetics
Genetic difference could be another possible factor in the higher rates of false positive RDT results observed in African settings. Hill et al. [55] reported extensive HLA class II DR-DQ polymorphism in The Gambia and Malawi and, citing other reports, stated that Africans have a greater HLA diversity and more class II haplotypes than Caucasians, Asians, Indians and Pacific Islanders. Extensive HLA class 1 polymorphism has also been reported in Africans [56] . The degree of similarity between a pathogen antigen and host HLA antigens will increase or decrease the level of immune response [57] . HLA polymorphism modifies the immune response to tuberculosis, leprosy, malaria, Klebsiella, Bartonella henselae, Chlamydia, Shigella, Yersinia, schistosomiasis, Chagas disease, dengue fever, HIV, HTLV-1, hepatitis B and hepatitis C, and may act alone or in combination with other genes conferring susceptibility to, or protection against, infectious diseases [57] .
Since different populations will have different HLA polymorphisms, and therefore different responses to non-HIV infectious diseases, the nature and frequency of cross-reactive antibodies can also be expected to be population dependent. In particular the performance of HIV diagnostic tests in Caucasian populations cannot be extrapolated to non-Caucasian populations. For example Santos et al. [58] reported that the frequency of indeterminate western blot reactivity varies significantly between regions and populations: 0.14%, 0.5%, This was observed in the development stage of one recombinant HIV antigen analyzed by mass spectrophotometry (Derryck Klarkowski, personal observation). This is unlikely to be problematic when stringent procedures are used to purify the target antigens, but is a potential cause of false positive reactions if poor quality tests are used in resource-limited settings where exposure to contaminated water sources is increased.
Unlikely causes of false positive HIV RDT results
Understanding the causes of false positive results is critical to effective programme management and patient care. However, reported causes have often been based on data with limited validation or are out-dated and unlikely to apply to current HIV RDTs. These postulated causes of false positive results with limited evidence are summarized in Table 3 .
The reports can be categorized as historical literature relating to first-generation immunoassay testing; studies over-generalizing problems with specific test formats or brands; reports later withdrawn or corrected; insufficient evidence; and theoretical risk.
First-generation immunoassay testing
Reports of false positives with first-generation immunoassays (associated with blood transfusion, chronic hepatic disease, pregnancy, leprosy and syphilis) are not relevant to current testing. Antigens used in manufacture of the tests were produced using viral lysate and processing commonly involved use of H9 cell lines, which resulted in some HLA class II antigens from the cells contaminating the antigen [1, 60, 61] .
Pregnancy
Pregnancy is one of the most commonly listed causes of HIV false positive reactions. Firstgeneration immunoassays were susceptible to allo-immunization in pregnancy crossreacting with contaminating cellular proteins from the cells used to culture the HIV virus [14, 24, [62] [63] [64] [65] . An association between current pregnancy and false positive HIV tests or between parity and false positive results for newer tests has not been demonstrated.
Recent studies suggest that the rate of false positives may be similar to that in other groups
and that the relatively high number of false positive results reported among pregnant women is a function of universal screening and the low overall incidence of HIV infection in pregnant women [63, 64, 66] .
Over-generalization
Problems can and do occur with specific test formats that are either resolved by the manufacturer or result in the test being withdrawn. Such reports should be treated with caution and not be cited as a general cause of false positive results.
For example, HIV false positive results related to an influenza vaccine in 1990 [67] were caused by a design defect, subsequently rectified, in the tests of a single manufacturer [13, 68, 69] . We can find no data to support direct cross-reactivity between influenza [73] repeated the protocol of Pearlman and Ballas [71] with 14 volunteers and found no false positive results. Although rabies shares glycoprotein sequences with gp120 [12] , the evidence appears to be against consistent false positivity being caused by the antigens used for rabies vaccination.
Evidence from the literature of other vaccinations as a cause for false positive immunoassay results is limited to a case control study from Brazil that investigated an association between increased rubella vaccination and an increase in false positive HIV tests among blood donors in São Paulo [74] .
Withdrawn or corrected reports can be particularly problematic when the modification is published by a different author or in a different journal. In the case of the influenza vaccination discussed earlier (in 'Over-generalization'), the original report was published in 1991 by MacKenzie et al. [67] and the correction by Buffington et al. [13] in 2004.
Insufficient evidence
This category includes reports with insufficient data and isolated reports that have not been corroborated by observations in other settings.
Examples include reports of false positive results caused by dengue (one publication, n=9) [75] ; hepatitis B (one publication, n=20 [76] ); retroviruses (one publication [77] but no evidence reported in two publications [14, 78] ); rabies vaccination (as described above) [73] ; a recent case report describing a false positive third-generation immunoassay result and a negative western blot in a patient admitted with visceral leishmaniasis [79] .
Theoretical risks
Reports in this group primarily relate to situations where there is peptide homology between HIV target antigens and infectious agents. Examples of proposed theoretical risk of interference include that from Candida [80] ; HTLV-1 [81] ; picornaviruses [59] and
Trichomonas [82] . There appear to be no data supporting interference with HIV testing by these infectious agents in actual testing practice. Further an additional modulating factor would need to be involved to account for the absence of positive reactions among all patients with a given infection.
Cross reactivity between antibodies to Schistosoma mansoni and HIV-1 peptides has been reported in one publication but further studies to investigate the association have not been published [83] .
Herpes simplex represents an interesting variation as Langedijk et al. [17] suggested homology between herpes and p24 antigen immobilized on a nitrocellulose matrix, which could have implications for some HIV RDT tests. However there appears to be no follow-up of this observation.
A further theoretical risk for sporadic or unexpected cross-reactivity is that HIV viral antigens processed by humans and bacteria have different characteristics that can potentially affect test performance, and this is relevant as the recombinant antigens used in RDTs are produced using bacteria. Craske et al. [84] report that differences in protein modification between eukaryotic and prokaryotic cells will produce pseudo-epitopes that are not related to the HIV antigen and that could cross-react with non HIV antibodies. A further potential problem with recombinant and peptide antigens is that, because the sequences are short, they may have a different tertiary structure to the same sequence as part of the much larger native protein and thereby form unexpected epitopes [59] . Both of these effects create the potential for unpredictable cross-reactivity.
Conclusions
HIV RDT results may vary significantly in different geographical areas, among different populations and over time [27] . Evaluation of tests with the use of a national serobank to guide algorithm development (as per current WHO guidelines) would go some way towards addressing this problem, however, the evaluation programme required is beyond the capacity of some countries and will not pick up variation between populations within a country. Validation at programme level may quickly become invalid with population changes, in transient populations or during outbreaks of infectious disease [45] .
In addition to population changes, the rapid rate of development of new tests and discontinuation of older ones may mean that algorithms become quickly outdated, necessitating repeats of the validation process. Furthermore, the shift towards increased sensitivity in new tests in response to the focus on early detection has led to inclusion of IgM detection and p24 antigen, which may increase the potential for non-specific reactivity [19, 40, 85, 86] . While this is likely to be of minimal significance in settings in which confirmatory testing is done routinely, it is likely to have major consequences in resourcelimited settings where confirmation is rare.
Our analysis of the literature suggests that HIV false positive results with current tests are more likely caused by polyspecific antibodies resulting from an independent infection than by direct antibody cross-reactivity with an independent infectious agent. We propose that The current widespread use of a tie-breaker algorithm, where two positive tests and one negative test are interpreted as an overall positive result, is highly susceptible to false results caused by cross-reactivity. The finding of both positive and negative results for the same blood sample is an alert to potential cross-reactivity and should not be followed by a single, deciding 'tie-breaker' test which may also be subject to the same cross-reactivity. HIV RDTS, despite their name, are screening rather than diagnostic tests and are clearly indicated as such by their manufacturers. We propose that the specificity of HIV RDT algorithms would be significantly improved by the universal implementation of confirmation testing. Confirmatory tests will not resolve all situations. However they do provide a safeguard for cross-reactivity against a single antigen (such as gp41) and are therefore a significant improvement on no confirmatory testing [7, 18] .
In order for this to be possible, there is an urgent need for the development of simpler and cheaper confirmatory tests. Where confirmatory testing is not yet implemented, immediate measures to reduce the risk should be introduced: diagnostic algorithms and manufacturer instructions should be changed to state that weak positive results are indeterminate and require further testing; and the use of tie-breaker algorithms should be discontinued.
Expert commentary
We propose that early B-lymphocyte response/polyspecific cross-reactivity can be a 
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All authors approved the final version of the article. [58] and 206 samples from persons with repeatedly reactive immunoassay and a control population [14]  One paper reported hepatitis B as the cause of two false positive HIV tests [76] but provides no evidence; other causes may equally have caused the false positivity  Herpes Celum et al. [14] reported no correlation between herpes simplex virus type 2 and HIV in 206 cases with repeatedly reactive immunoassay and a control population. Suggested homology between herpes and p24 antigen that is immobilized on a nitrocellulose matrix, which could have implications for some HIV RDT tests [17] Cause 1 st G OG W ID HTLV 1/2 HTLV-1 and HIV share a closely related gp24 antigen [81] and come from the same viral family. Early reports suggested possible cross-reactivity with HTLV-1/2 [11, 58] (and the related animal lentiviruses) [77] , but consensus now is that cross-reactivity between HTLV-1/2 and HIV is at best very uncommon  Leishmaniasis Insufficient evidence with a single immunoassay false positive [39, 79] ; report of problems with an EIA test later withdrawn [70]  Myeloma Very limited data related to first-generation immunoassay [99] . Possibly related, Melles et al. [54] report a correlation between HIVSPOT and heavy smoking, and speculate that the higher plasma viscosity in smokers may cause interference with RDTs  Picornaviruses Very limited data. Picornaviruses are reported to be widespread and cause annual occurrences of gastrointestinal and respiratory influenza [59] . Some studies suggest a possible homology between HIV and picornviral proteins [100] but there appears to be no evidence this is a cause of HIV false positives  Pregnancy Historic; publications related to first-generation immunoassay only [66]  Retroviruses: bovine, caprine, feline
Other retroviruses within the lentivirus group have been suggested as a source of cross reactive antibodies; supportive evidence includes the existence of analogous glycoprotein sequences and observation of crossed antigenic reactivity summarized by Tesoro-Cruz et al. [77] . However cross-reactivity, even it occurred, is likely to be in the gag region and therefore unlikely to affect HIV RDT testing. No association found between indeterminate HTLV-1, bovine immunodeficiency virus and bovine and feline leukemia virus WBs and false positive immunoassay results in two reports [14, 101] . 

Trichomonas
Fiori et al. [82] reported that although anti-gp41 can cross-react with the human form of alpha-actin only 3/140 sera containing anti-Trichomonas alpha-actin antibodies reacted with two immunoassay tests (2.8% false positive rate) and conclude that this data do not support cross-reactivity between Trichomonas and HIV testing 
Tuberculosis (Mycobacterium tuberculosis)
Despite the high incidence of tuberculosis in populations being tested for HIV, cross-reactivity has not been reported. Meles et al. [54] reported no association with tuberculosis in an Ethiopian study of indeterminate WB cases (n=91) 
